Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane((R))) by the Pediatric Preclinical Testing Program (PPTP)

摘要

BackgroundNanoparticle albumin-bound paclitaxel (nab-paclitaxel, Abraxane((R))) is FDA approved for the treatment of several adult cancers. Antimitotic agents are essential components for curative therapy of pediatric solid tumors, although taxanes have shown limited activity. Because of the novel formulation, nab-paclitaxel was evaluated against a limited series of Pediatric Preclinical Testing Program (PPTP) solid tumors.